Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Genflow Biosciences Plc ( (GB:GENF) ).
In 2024, Genflow Biosciences achieved significant advancements in developing therapeutics aimed at promoting longer and healthier lives by targeting the SIRT6 gene. The company progressed to the pre-IND phase for their MASH treatment GF-1002, partnered with Exothera SA for manufacturing readiness, and initiated a veterinary trial for aging dogs. Additionally, they innovated in Werner syndrome research through human-derived organoids and made strides in addressing sarcopenia with collaborations, positioning themselves for clinical trials and potential market impact.
More about Genflow Biosciences Plc
Founded in 2020, Genflow Biosciences Plc is a UK-based biotechnology company with R&D facilities in Belgium, focusing on pioneering gene therapies to slow down aging. Their main product, GF-1002, involves the delivery of a centenarian variant of the SIRT6 gene to promote longer, healthier lives, addressing the growing global aging population’s financial, emotional, and social impacts.
YTD Price Performance: 1.74%
Average Trading Volume: 923,467
Technical Sentiment Consensus Rating: Buy
See more data about GENF stock on TipRanks’ Stock Analysis page.
